TDI 01 - Beijing Tide Pharmaceutical/Graviton
Alternative Names: TDI-01Latest Information Update: 28 Mar 2025
At a glance
- Originator Beijing Tide Pharmaceutical
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Neuroprotectants; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Graft-versus-host disease
- No development reported Cancer; CNS disorders; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Viral infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Cancer in China
- 28 Mar 2025 No recent reports of development identified for preclinical development in CNS-disorders in China
- 28 Mar 2025 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in China